Susana D. L. C.
- Country
- Spain
- Department
- Medical oncology
Research Overview
Data & Insights
Has run more than one trial at 0 of 86 partner sites.
Specializations
Hematologic Malignancies
Susana De la Cruz leads investigations into Acute Myeloid Leukemia, Myelodysplastic Syndrome and Multiple Myeloma, focusing on targeted therapeutics and disease‑specific biomarkers.
- Novel agents for relapsed/refractory AML
- Combination strategies in high‑risk MDS
- Immunotherapy approaches for plasma cell dyscrasias
Her studies integrate molecular profiling to refine risk stratification and personalize treatment.
Advanced Solid Tumors
The investigator focuses on Breast Cancer, Non‑Small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer and Ovarian Cancer, emphasizing precision medicine across metastatic settings.
- Biomarker‑driven therapies for HER2‑negative disease
- KRAS‑mutant targeted treatments in colorectal and lung cancers
- Combination immuno‑oncology regimens for triple‑negative breast cancer
Clinical effort is centered on expanding therapeutic options for patients with refractory disease.
Amyloid and Light‑Chain Disorders
Research activity includes AL Amyloidosis and ATTR Amyloidosis, targeting organ involvement and novel anti‑amyloid agents.
- Antibody‑based clearance of light‑chain deposits
- TTR stabilizers for cardiac amyloid disease
- Biomarker monitoring of treatment response
These studies aim to improve survival and quality of life for patients with systemic amyloidosis.
Autoimmune and Inflammatory Diseases
Susana De la Cruz investigates Systemic Lupus Erythematosus, Systemic Sclerosis and Idiopathic Inflammatory Myopathy, exploring disease‑modifying strategies.
- Targeted cytokine inhibition in refractory lupus nephritis
- Fibrotic pathway modulation in systemic sclerosis
- Immune‑tolerizing approaches for inflammatory myopathies
Her work bridges immunology and clinical practice to address unmet therapeutic needs.
Infectious Lung Diseases
The investigator also addresses Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial Lung Infection caused by Mycobacterium avium Complex, focusing on antimicrobial regimens and host response.
- Optimized antibiotic combinations for MAC disease
- Adjunctive host‑directed therapies
- Long‑term outcome monitoring in chronic infection
These efforts aim to reduce morbidity and improve treatment durability in complex pulmonary infections.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.